Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Clinical trial NCT07517198 · RECRUITING

Trial details

NCT number: NCT07517198
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumor Small Cell Lung Cancer (SCLC)High Grade Neuroendocrine Cancer Small Cell Carcinomas of Non-lung Origin Non-small Cell Lung Cancer (NSCLC)Prostate Cancer Ovarian Cancer Renal Carcinoma (Clear and Non-clear Cell)Head and Neck Squamous Cell Carcinoma (HNSCC)Hepatic Cancer Gastric Cancer Triple-negative Breast Cancer (TNBC)

Start date: 2026-04-13
Primary completion: 2029-03-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.